Mean plasma concentrations of mobocertinib A. following the first oral administration of mobocertinib on Cycle 1, Day 1 and B. following repeated oral dosing on Cycle 2, Day 1 in patients with NSCLC in the dose-escalation study (semi-log scale).
Abbreviations: NSCLC, non–small cell lung cancer.
Preliminary pharmacokinetic data as January 27, 2020.